Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 188Neoplasm Metastasis 152Neoplasms 141Leukemia, Myeloid, Acute 139Colorectal Neoplasms 132Breast Neoplasms 122Melanoma 96Ovarian Neoplasms 94Prostatic Neoplasms 89Recurrence 88Multiple Myeloma 84Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66Triple Negative Breast Neoplasms 58Glioma 58Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Endometrial Neoplasms 51Carcinoma, Renal Cell 49Brain Neoplasms 49Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 46Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 41Sarcoma 40

Interventions

trametinib 1dabrafenib 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Thyroid Carcinoma, Anaplastic × 90 days × Clear all
NCT07485569 2026-04-15

REPOTHYROID-II

Radboud University Medical Center

Phase 1 Not yet recruiting
10 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1 Recruiting
6 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡